Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 11/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051267 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL4560704 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL102246 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL2067916 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL7514132 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL16875635 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL3500436 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL18057165 | 0.74 | DYRK1A (0.47) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL3514678 | 0.74 | DYRK1A (0.70) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL8933370 | 0.72 | DYRK1A (0.50) | DYRK1ACLK4MAPK14MAP4K4PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111205448-B | Method for preparing polycarbonate by catalysis | 中国科学院过程工程研究所 | 2021-07-02 | — | — | CN | claimed |
| CN-111205448-A | Method for preparing polycarbonate by catalysis | 中国科学院过程工程研究所 | 2020-05-29 | — | — | CN | claimed |
| EP-3271361-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL MYERS SQUIBB CO (US) | 2020-04-22 | — | — | EP | claimed |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | claimed |
| EP-3271361-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | Bristol-Myers Squibb Company (US) | 2018-01-24 | — | — | EP | claimed |
| WO-2016149437-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-22 | — | — | WO | claimed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-118005640-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| CN-111205448-B | Method for preparing polycarbonate by catalysis | 中国科学院过程工程研究所 | 2021-07-02 | — | — | CN | disclosed |
| US-9233968-B1 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233968-B1 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233968-B1 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-7306631-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1732509-A1 | KERATIN DYEING COMPOSITIONS BICYCLIC 5-6 HETEROAROMATIC DYEING COMPOUNDS WITH ONE RING NITROGEN JUNCTION | The Procter and Gamble Company (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097052-A1 | KERATIN DYEING COMPOSITIONS BICYCLIC 5-6 HETEROAROMATIC DYEING COMPOUNDS WITH ONE RING NITROGEN JUNCTION | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | TNF, TNFRSF1A, TNFRSF9 | DYRK1A 1290/4885CLK4 4207/4885MAPK14 1441/4885 |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, JUP | DYRK1A 2166/4885CLK4 1298/4885MAPK14 1211/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | DYRK1A 4540/4885CLK4 2711/4885MAPK14 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.